Sign up to access all valuation multiples
ImmunoPrecise Antibodies Ltd is an AI-driven biotherapeutic research, technology and scientifically robust life science company focused on the discovery and development of next-generation biologics. The Company combines scientific expertise with proprietary technologies such as its LENSai platform to accelerate drug discovery and improve decision-making across complex biological systems. IPA has several subsidiaries in North America and Europe, supporting global partners in advancing novel therapeutics, diagnostics, and translational research.
1983
102
LTM Revenue $13.6M
Last FY EBITDA -$28.9M
$93.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
MindWalk Holdings has a last 12-month revenue (LTM) of $13.6M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, MindWalk Holdings achieved revenue of $24.5M and an EBITDA of -$28.9M.
MindWalk Holdings expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MindWalk Holdings valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.6M | XXX | $24.5M | XXX | XXX | XXX |
| Gross Profit | $8.1M | XXX | $13.5M | XXX | XXX | XXX |
| Gross Margin | 60% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$28.9M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -118% | XXX | XXX | XXX |
| EBIT | -$8.8M | XXX | -$12.2M | XXX | XXX | XXX |
| EBIT Margin | -65% | XXX | -50% | XXX | XXX | XXX |
| Net Profit | -$11.5M | XXX | -$30.2M | XXX | XXX | XXX |
| Net Margin | -85% | XXX | -123% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 5, 2025, MindWalk Holdings's stock price is $2.
MindWalk Holdings has current market cap of $91.8M, and EV of $93.8M.
See MindWalk Holdings trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $93.8M | $91.8M | XXX | XXX | XXX | XXX | $-0.47 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 5, 2025, MindWalk Holdings has market cap of $91.8M and EV of $93.8M.
MindWalk Holdings's trades at 3.8x EV/Revenue multiple, and -3.5x EV/EBITDA.
Equity research analysts estimate MindWalk Holdings's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MindWalk Holdings has a P/E ratio of -5.7x.
See valuation multiples for MindWalk Holdings and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $91.8M | XXX | $91.8M | XXX | XXX | XXX |
| EV (current) | $93.8M | XXX | $93.8M | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 3.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -3.5x | XXX | XXX | XXX |
| EV/EBIT | -7.7x | XXX | -7.4x | XXX | XXX | XXX |
| EV/Gross Profit | 8.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -5.7x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -14.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMindWalk Holdings's last 12 month revenue growth is 23%
MindWalk Holdings's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.3M for the same period.
MindWalk Holdings's rule of 40 is -87% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MindWalk Holdings's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MindWalk Holdings and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 23% | XXX | 2% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -110% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -87% | XXX | -87% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 18% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 105% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MindWalk Holdings acquired XXX companies to date.
Last acquisition by MindWalk Holdings was XXXXXXXX, XXXXX XXXXX XXXXXX . MindWalk Holdings acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was MindWalk Holdings founded? | MindWalk Holdings was founded in 1983. |
| Where is MindWalk Holdings headquartered? | MindWalk Holdings is headquartered in United States of America. |
| How many employees does MindWalk Holdings have? | As of today, MindWalk Holdings has 102 employees. |
| Who is the CEO of MindWalk Holdings? | MindWalk Holdings's CEO is Dr. Jennifer L. Bath. |
| Is MindWalk Holdings publicy listed? | Yes, MindWalk Holdings is a public company listed on NAS. |
| What is the stock symbol of MindWalk Holdings? | MindWalk Holdings trades under IPA ticker. |
| When did MindWalk Holdings go public? | MindWalk Holdings went public in 2010. |
| Who are competitors of MindWalk Holdings? | Similar companies to MindWalk Holdings include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of MindWalk Holdings? | MindWalk Holdings's current market cap is $91.8M |
| What is the current revenue of MindWalk Holdings? | MindWalk Holdings's last 12 months revenue is $13.6M. |
| What is the current revenue growth of MindWalk Holdings? | MindWalk Holdings revenue growth (NTM/LTM) is 23%. |
| What is the current EV/Revenue multiple of MindWalk Holdings? | Current revenue multiple of MindWalk Holdings is 5.0x. |
| Is MindWalk Holdings profitable? | Yes, MindWalk Holdings is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
